Pharmagen Stock Performance
| PHRX Stock | USD 0.00001 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Pharmagen are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Pharmagen are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Pharmagen showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 45:1 | Last Split Date 2011-12-07 |
1 | Exosome Research Products Industry Research Report 2023-2030, Featuring AMS, Bio-Techne, Lonza, Miltenyi Biotech, Nanosomix, Norgen Biotek, NX Pharmagen, Qiagen... | 12/03/2024 |
| Total Cashflows From Investing Activities | -56.7 K |
Pharmagen |
Pharmagen Relative Risk vs. Return Landscape
If you would invest 0.01 in Pharmagen on November 19, 2024 and sell it today you would lose (0.01) from holding Pharmagen or give up 90.0% of portfolio value over 90 days. Pharmagen is currently generating 15.0% in daily expected returns and assumes 129.9609% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Pharmagen, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pharmagen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharmagen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pharmagen, and traders can use it to determine the average amount a Pharmagen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1154
| Best Portfolio | Best Equity | PHRX | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 129.96 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Pharmagen is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharmagen by adding it to a well-diversified portfolio.
Pharmagen Fundamentals Growth
Pharmagen Stock prices reflect investors' perceptions of the future prospects and financial health of Pharmagen, and Pharmagen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharmagen Stock performance.
| Return On Asset | -0.59 | ||||
| Profit Margin | (1.33) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 5.93 M | ||||
| Shares Outstanding | 517.08 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Sales | 0.08 X | ||||
| Revenue | 4.81 M | ||||
| Gross Profit | 2.75 M | ||||
| EBITDA | (2.13 M) | ||||
| Net Income | (6 M) | ||||
| Cash And Equivalents | 264.67 K | ||||
| Total Debt | 2.16 M | ||||
| Current Ratio | 0.10 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (692.07 K) | ||||
| Market Capitalization | 361.95 K | ||||
| Total Asset | 1.28 M | ||||
| Working Capital | (7.46 M) | ||||
| Current Asset | 837 K | ||||
| Current Liabilities | 8.29 M | ||||
About Pharmagen Performance
Evaluating Pharmagen's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Pharmagen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharmagen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 25.45 | 22.62 | |
| Return On Tangible Assets | (4.60) | (4.83) | |
| Return On Capital Employed | 0.29 | 0.26 | |
| Return On Assets | (4.53) | (4.76) | |
| Return On Equity | 0.77 | 0.68 |
Things to note about Pharmagen performance evaluation
Checking the ongoing alerts about Pharmagen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pharmagen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharmagen is way too risky over 90 days horizon | |
| Pharmagen has some characteristics of a very speculative penny stock | |
| Pharmagen appears to be risky and price may revert if volatility continues | |
| Pharmagen has high likelihood to experience some financial distress in the next 2 years | |
| Pharmagen currently holds 2.16 M in liabilities. Pharmagen has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Pharmagen's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 4.81 M. Net Loss for the year was (6 M) with profit before overhead, payroll, taxes, and interest of 2.75 M. | |
| Pharmagen currently holds about 264.67 K in cash with (692.07 K) of positive cash flow from operations. | |
| Pharmagen has a frail financial position based on the latest SEC disclosures |
- Analyzing Pharmagen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharmagen's stock is overvalued or undervalued compared to its peers.
- Examining Pharmagen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharmagen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharmagen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharmagen's stock. These opinions can provide insight into Pharmagen's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pharmagen Stock Analysis
When running Pharmagen's price analysis, check to measure Pharmagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmagen is operating at the current time. Most of Pharmagen's value examination focuses on studying past and present price action to predict the probability of Pharmagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmagen's price. Additionally, you may evaluate how the addition of Pharmagen to your portfolios can decrease your overall portfolio volatility.